Table 2.
Immune-mediated adverse effect (AE) by steroids timing (n=247)
| Immune-mediated AE | Overall (n=247) | <2 months steroids (n=129) | ≥2 months steroids (n=118) | P value |
| Total adverse effects | 137 (55.47) | 66 (48.18) | 71 (51.82) | 0.1548 |
| Dermatitis | 38 (15.38) | 23 (60.53) | 15 (39.47) | 0.2655 |
| Colitis | 38 (15.38) | 17 (44.74) | 21 (55.26) | 0.3150 |
| Pneumonitis | 34 (13.76) | 19 (55.88) | 15 (44.12) | 0.6458 |
| Hepatitis | 21 (8.50) | 12 (57.14) | 9 (42.86) | 0.6373 |
| Nephritis | 1 (3.64) | 3 (33.33) | 6 (66.67) | 0.3171 |
| Hypothyroid/hyperthyroid | 39 (15.78) | 14 (35.90) | 25 (64.10) | 0.0261* |
| Adrenal insufficiency | 4 (1.62) | 0 (0.00) | 4 (100.00) | 0.0507 |
| Hypophysitis | 4 (1.62) | 3 (75.00) | 1 (25.00) | 0.3579 |
| Uveitis | 1 (0.40) | 0 (0.00) | 1 (100.00) | 0.2948 |
*Statistically significant at 0.05.